Today on Outsourcing-Pharma.com   Karma for big pharma? Sanofi-Aventis caught out by Inyx collapse Explosions at two pharma plants Thermo continues fishing in India Survey asks: what to do about counterfeit drugs? Big pharma reaches to Summit for zebrafish safety screening

Related Industry News   Bayer banishes high dose MS drug Takeda sleeping drug takes 'Worst Product Award' Another safety scare for Roche Wellcome boost for Alzheimer's research

Breaking News on Outsourcing Pharma
Daily  Tuesday 30 October 2007		Forward to a colleague

	Technical / White Paper Benefits of integrating human tissue research in drug discovery The benefits of integrating human tissue research into drug discovery and development programs are in the confidence that they provide in the selection of the NCEs most likely to succeed in the clinic, and doing this in the most financially efficient way... Click Here Access Full Stories Karma for big pharma? Sanofi-Aventis caught out by Inyx collapse Sanofi-Aventis has had to take Inyx USA to court after it failed to deliver on a contract manufacturing and supply agreement, a situation that Aventis feared could "seriously harm its interests". There may be important... Read Explosions at two pharma plants Two pharmaceutical companies have faced explosions at their plants in the last week, local media reported... Read Thermo continues fishing in India Thermo Fisher Scientific continues to fish for new opportunities in India and has begun setting up a new clinical services base in the country... Read Survey asks: what to do about counterfeit drugs? Action should be taken to curb the counterfeit drug trade, but not via legal intervention, the results of a European survey say... Read Big pharma reaches to Summit for zebrafish safety screening Summit (formerly Vastox) has signed a $450,000 (€312,000) deal with one of the world's top five pharma firms to enable it to use Summit's zebrafish-platform in its drug safety programme... Read
	All News Headlines for: October | September | August
	Related Industry News Bayer banishes high dose MS drug Bayer Schering Pharma this week announced that it has scrapped plans to introduce a double-dose version of its top-selling multiple sclerosis (MS) drug Betaferon (interferon beta-1b) by the end of the year following... Read Takeda sleeping drug takes 'Worst Product Award' Japanese pharma firm Takeda beat off strong competition from the likes of Coca-Cola to take home the dubious honour of Consumer International's 'Worst Product' award thanks to its sleeping pill ad... Read Another safety scare for Roche In another safety concern over a long-approved drug, Roche has been forced to add new warnings to its anti-transplant rejection drug CellCept (mycophenolate mofetil (MMF)) amid the news that it is associated with... Read Wellcome boost for Alzheimer's research The UK's largest charity, the Wellcome Trust, has awarded £1.3m (€1.9m) to fund the world's largest ever genome-wide association study to identify the genetic origins of Alzheimer's disease... Read Weekly Comment Pfizer partners in shock after surprise Exubera exit We've all cringed at stories of people dumping their partners via text message but in the world of business, Pfizer seems to have taken things to a new level when its Exubera partners were allegedly left to find out the product was being scrapped through a press release. Read Previous Headlines Big pharma lends a helping hand Despite often attracting a barrage of negative publicity, particularly in regard to a perception of putting profits before people, big pharma firms are still capable of showing their human side in times of crisis... Read Pfizer to cut another 200 jobs Pfizer is already cutting jobs in relation to its failed Exubera with the announcement that some 200 jobs are to go at the drug giant's Portage and Kalamazoo sites, according to local media reports... Read Contract manufacturing news in brief Novavax, Cobra Biomanufacturing, Catalent Pharma Solutions, and Suven Life Sciences have all recently announced new contract manufacturing news... Read Major Singapore investment for Novartis Swiss pharma Novartis today announced the largest manufacturing investment in its history, revealing plans for a $700m (€486.5m) biotech facility to be built alongside its new solid dose plant in the low... Read Ranbaxy's statin a drag on PPD's bottom line PPD's decision to in-license an investigational compound is proving to be a drag on its bottom line as the firm continues to seek a development partner for the drug... Read Technical / White Papers, Case studies, Web casts Benefits of integrating human tissue research in drug discovery - Technical / White Paper Product Innovation Alerts - Free of Charge Indicate your research interests and receive alerts on relevant products and market innovations Analytical testing, QC Bulk ingredients Contract sales & marketing Data management Drug delivery, formulation Fill & finish, packaging Phase I-II Phase III-IV Preclinical Product & Supplier News - Contract Manufacturing Regulatory affairs Supply chain, logistics Validation services

	Free Newsletters for Pharmaceuticals Access now !Choose from over 20 industry e-newsletters Access Decision News Media e-newsletters for the food, beverage & nutrition industries, click here
	Forward to a colleague

	To continue to receive this newsletter in your inbox, please add newsletter@OutSourcing-Pharma.com to your address book
	Update preferences | Change your email address | Unsubscribe
	Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback
	© 2007 - Decision News Media S.A.S - All Rights Reserved Le Belem - 355, rue Vendemiaire - 34000 Montpellier - France http://www.decisionnewsmedia.com